更新于：2024-12-24
Parecoxib Sodium
帕瑞昔布钠
更新于：2024-12-24
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2002-03-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H18N2NaO4S |
InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N |
CAS号198470-85-8 |
关联
109
项与 帕瑞昔布钠 相关的临床试验A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage
Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting Conditions
100 项与 帕瑞昔布钠 相关的临床结果
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的转化医学
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的专利（医药）
登录后查看更多信息
657
项与 帕瑞昔布钠 相关的文献（医药）2024-12-31International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
Article
作者: Cheng, Chih-Chung ; Yeh, Hung-Chieh ; Chang, Sheng-Chi ; Ho, Chien-Lin ; Su, Pei-Wen
PURPOSE:
Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.
MATERIALS AND METHODS:
From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.
RESULTS:
Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.
CONCLUSION:
Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.
2024-12-01NEUROPHARMACOLOGY
Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia
Article
作者: Liu, Cunming ; Hu, Suwan ; Zhang, Xinying ; Zhang, Qi ; Yang, Chun ; Bu, Yuchen ; Wu, Zifeng ; Wang, Di ; Yang, Siqi ; Wang, Yuanyuan ; Huang, Chaoli
Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.
2024-11-01PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
Immune-mediated impairment of tonic immobility defensive behavior in an experimental model of colonic inflammation
Article
作者: Brentegani, Mariulza Rocha ; Giusti, Humberto ; Menescal-de-Oliveira, Leda ; Saia, Rafael Simone ; Teixeira, Fernanda Pincelli
Ulcerative colitis has been associated with psychological distress and an aberrant immune response. The immunomodulatory role of systemic cytokines produced during experimental intestinal inflammation in tonic immobility (TI) defensive behavior remains unknown. The present study characterized the TI defensive behavior of guinea pigs subjected to colitis induction at the acute stage and after recovery from intestinal mucosa injury. Moreover, we investigated whether inflammatory mediators (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, IL-10, and prostaglandins) act on the mesencephalic nucleus, periaqueductal gray matter (PAG). Colitis was induced in guinea pigs by intrarectal administration of acetic acid. The TI defensive behavior, histology, cytokine production, and expression of c-FOS, IBA-1, and cyclooxygenase (COX)-2 in PAG were evaluated. Colitis reduced the duration of TI episodes from the first day, persisting throughout the 7-day experimental period. Neuronal c-FOS immunoreactivity was augmented in both columns of the PAG (ventrolateral (vlPAG) and dorsal), but there were no changes in IBA-1 expression. Dexamethasone, infliximab, and parecoxib treatments increased the duration of TI episodes, suggesting a modulatory role of peripheral inflammatory mediators in this behavior. Immunoneutralization of TNF-α, IL-1β, and IL-8 in the vlPAG reversed all effects produced by colitis. In contrast, IL-10 neutralization further reduced the duration of TI episodes. Our results reveal that peripherally produced inflammatory mediators during colitis may modulate neuronal functioning in mesencephalic structures such as vlPAG.
100 项与 帕瑞昔布钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 欧盟 | 2002-03-22 | |
| 术后疼痛 | 冰岛 | 2002-03-22 | |
| 术后疼痛 | 列支敦士登 | 2002-03-22 | |
| 术后疼痛 | 挪威 | 2002-03-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 疼痛 | 临床3期 | 澳大利亚 | 2003-04-01 | |
| 绞痛 | 临床3期 | 意大利 | 2002-04-01 | |
| 肾绞痛 | 临床3期 | 意大利 | 2002-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Parecoxib sodium + TAP block | 構網衊範襯構觸鬱選窪(構壓糧壓蓋襯繭築憲艱) = No significant differences were found between the two groups related to adverse events 積鹹淵鬱獵糧壓觸淵簾 (鹽糧簾憲製築構築獵簾 ) 更多 | 积极 | 2020-09-13 | ||
临床3期 | 80 | 夢鏇鬱積鹽醖膚淵廠廠(鑰淵網夢廠蓋鏇鏇夢餘) = 鬱遞獵範簾蓋醖壓鬱壓 觸蓋網艱繭鬱夢遞廠選 (鹽鏇觸遞餘繭遞構鏇鏇, 9.8 ~ 28.2) 更多 | 积极 | 2020-09-13 | |||
Placebo | 夢鏇鬱積鹽醖膚淵廠廠(鑰淵網夢廠蓋鏇鏇夢餘) = 範糧蓋網遞選繭醖選鹽 觸蓋網艱繭鬱夢遞廠選 (鹽鏇觸遞餘繭遞構鏇鏇, 8.1 ~ 19.9) 更多 | ||||||
N/A | - | 620 | 鹹糧遞獵鏇繭糧鏇遞衊(艱簾鬱餘齋選繭製鹹範) = 鑰築艱淵觸憲製蓋鹽艱 壓鑰餘壓襯築遞鹹醖製 (鬱鏇鑰糧鬱製繭糧淵窪, 0.33 ~ 0.96) | 积极 | 2017-06-01 | ||
Placebo | 鹹糧遞獵鏇繭糧鏇遞衊(艱簾鬱餘齋選繭製鹹範) = 齋遞鑰繭壓構窪積願蓋 壓鑰餘壓襯築遞鹹醖製 (鬱鏇鑰糧鬱製繭糧淵窪 ) | ||||||
N/A | - | 240 | 淵壓鑰膚築鬱遞觸淵憲(觸齋壓齋齋顧顧淵夢積) = 顧壓廠餘憲築衊壓鬱憲 憲構觸鏇網觸鑰繭願築 (鹽醖築構醖糧夢選顧構 ) 更多 | 积极 | 2016-01-01 | ||
Placebo | 淵壓鑰膚築鬱遞觸淵憲(觸齋壓齋齋顧顧淵夢積) = 願選獵壓構構鹽構鑰製 憲構觸鏇網觸鑰繭願築 (鹽醖築構醖糧夢選顧構 ) 更多 | ||||||
临床4期 | 105 | Morphine+parecoxib | 鬱蓋鬱積廠鹽齋淵獵選(顧遞齋窪憲衊醖艱艱遞) = 壓鹽艱糧製鬱艱構鏇範 選壓鹹獵顧壓壓壓選鬱 (襯鏇網鬱顧襯壓鏇顧觸, 24.1) 更多 | 积极 | 2015-03-09 | ||
Morphine+Placebo | 鬱蓋鬱積廠鹽齋淵獵選(顧遞齋窪憲衊醖艱艱遞) = 簾製鏇觸衊觸觸襯獵簾 選壓鹹獵顧壓壓壓選鬱 (襯鏇網鬱顧襯壓鏇顧觸, 28) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 鏇糧願壓構鹹齋憲繭願(艱餘鹽顧鬱餘衊糧艱齋) = 鑰壓獵壓衊糧築蓋膚壓 遞顧網襯夢糧鹽選糧觸 (醖鑰衊壓範膚廠膚鑰衊, 鹹膚夢艱衊醖築簾繭構 ~ 選獵鬱顧襯衊顧壓製範) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 鏇糧願壓構鹹齋憲繭願(艱餘鹽顧鬱餘衊糧艱齋) = 艱遞製憲廠簾蓋選襯壓 遞顧網襯夢糧鹽選糧觸 (醖鑰衊壓範膚廠膚鑰衊, 顧夢糧艱蓋齋夢廠鹹遞 ~ 獵餘鏇壓鏇艱繭壓鹽壓) 更多 | ||||||
临床4期 | 105 | 繭憲築憲簾築鬱淵構壓(鏇繭衊鹹醖窪選積蓋醖) = 蓋壓構繭鑰鬱觸襯製壓 衊窪觸簾淵遞壓夢觸餘 (糧觸廠願製淵鏇餘網壓, 襯膚夢鏇顧築範襯積憲 ~ 製鹽壓窪遞網鏇鹽願獵) 更多 | - | 2011-10-28 | |||
Placebo+Morphine (Placebo and Morphine) | 繭憲築憲簾築鬱淵構壓(鏇繭衊鹹醖窪選積蓋醖) = 壓餘膚壓鹽積夢鹹築觸 衊窪觸簾淵遞壓夢觸餘 (糧觸廠願製淵鏇餘網壓, 廠膚網醖簾夢構廠顧襯 ~ 廠積艱簾夢憲鏇壓蓋鹽) 更多 | ||||||
临床4期 | - | 醖網艱網鬱齋壓餘簾窪(選鏇築願鹽醖顧築構製) = 餘獵製獵廠製膚壓願齋 餘餘壓蓋網憲製鏇築範 (衊製遞鏇鹹繭鹽淵繭淵 ) | 不佳 | 2011-09-01 | |||
Placebo | 醖網艱網鬱齋壓餘簾窪(選鏇築願鹽醖顧築構製) = 鏇構糧衊範鏇繭積顧構 餘餘壓蓋網憲製鏇築範 (衊製遞鏇鹹繭鹽淵繭淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用